Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | GALR3 | O60755 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21675715 | 0.91 | MEN1 (0.56) | MEN1KMT2AMMP1KDM4EALDH1A1 | |
| SCHEMBL18666152 | 0.90 | KDR (0.53) | KDRMEN1KMT2AMMP1KDM4E | |
| SCHEMBL18666250 | 0.89 | KDR (0.48) | KDRMMP1LMNAPOLBGALR3 | |
| SCHEMBL18666157 | 0.85 | ALDH1A1 (0.48) | KDRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL18666249 | 0.85 | RAB9A (0.48) | KDRMEN1KMT2AMMP1LMNA | |
| SCHEMBL18666440 | 0.83 | KDR (0.61) | KDRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL18666246 | 0.81 | DGAT2 (0.47) | KDRMMP1ALDH1A1MITFPOLB | |
| SCHEMBL14413344 | 0.79 | MEN1 (0.72) | KDRMEN1KMT2ALMNAMITF | |
| SCHEMBL18666611 | 0.79 | MEN1 (0.51) | MEN1KMT2AALDH1A1LMNAMITF | |
| SCHEMBL18666437 | 0.77 | MEN1 (0.48) | KDRMEN1KMT2AMMP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023172880-A2 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2022232509-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE (US) | 2022-11-03 | — | — | WO | disclosed |
| US-11345656-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210078938-A1 | PCNA INHIBITORS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2021-03-18 | — | — | US | disclosed |
| US-10913706-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200216386-A1 | PCNA INHIBITORS | UNITED STATES GOVERNMENT | 2020-07-09 | — | — | US | disclosed |
| US-10550070-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2017049206-A1 | PCNA INHIBITORS | CITY OF HOPE (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913706-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | KDR 2962/4885MEN1 2671/4885KMT2A 1384/4885 |
| US-20210078938-A1 | PCNA INHIBITORS | PCNA, MKI67, PCLAF | KDR 2962/4885MEN1 2671/4885KMT2A 1384/4885 |
| US-11345656-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | KDR 2962/4885MEN1 2671/4885KMT2A 1384/4885 |
| US-10550070-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | KDR 2962/4885MEN1 2671/4885KMT2A 1384/4885 |
| US-20200216386-A1 | PCNA INHIBITORS | PCNA, MKI67, PCLAF | KDR 2962/4885MEN1 2671/4885KMT2A 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.